
Johnson & Johnson's Covid-19 vaccine candidate begins Phase 3 trials.
Veuer’s Maria Mercedes Galuppo has the story.
Johnson & Johnson's Covid-19 vaccine candidate begins Phase 3 trials.
Veuer’s Maria Mercedes Galuppo has the story.
Pfizer announced Friday it is seeking emergency approval from US regulators for its Covid-19 vaccine, which has shown 95 percent..